<?xml version="1.0" encoding="UTF-8"?>
<ref id="B63">
 <label>63.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Haga</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Nagata</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Okamura</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Sata</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>N</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds</article-title>. 
  <source>Antiviral Res.</source> (
  <year>2010</year>) 
  <volume>85</volume>:
  <fpage>551</fpage>â€“
  <lpage>5</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id>
  <?supplied-pmid 19995578?>
  <pub-id pub-id-type="pmid">19995578</pub-id>
 </mixed-citation>
</ref>
